The company fell well short of expectations for its fourth quarter.
Coherus BioSciences: Q4 Earnings Snapshot
As promised, Coherus is using the proceeds of a recent divestiture to pay down debt and reduce interest expenses.
The positive reaction to Coherus' sale of its ophthalmology franchise to Sandoz didn't last long.
Coherus is divesting its non-core ophthalmology franchise.
Coherus finally received FDA approval for its Udenyca OnBody injector system.
Stocks that are trading heavily or have substantial price changes on Wednesday: Cytokinetics, New York Times rise; Iovance Biotherapeutics fall
These two biotech stocks could be poised for a trend reversal.
The company has been punished harshly for a worse-than-expected quarter.
Coherus missed estimates for the third quarter and lowered its full-year outlook.